Amphastar Pharmaceuticals, Inc. (AMPH) stock
Close on Nov 12, 2026Market cap $1.23BP/E 13.1Yield –
Earnings
Amphastar Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Amphastar Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $207.60M | +8.2% | $0.87 | $1.14 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026during market hours | $183.90M | +5.4% | $0.67 | $0.91 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026during market hours | $171.20M | +0.4% | $0.14 | $0.42 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026during market hours | $183.10M | -1.8% | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025during market hours | $191.80M | +0.3% | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025during market hours | $174.40M | -4.4% | $0.64 | $0.85 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025during market hours | $170.50M | -0.8% | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025during market hours | $186.50M | +4.7% | $0.74 | $0.92 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024during market hours | $191.20M | +5.9% | $0.78 | $0.96 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024during market hours | $182.40M | +25.2% | $0.73 | $0.94 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024during market hours | $171.80M | +22.7% | $0.81 | $1.04 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024during market hours | $178.10M | +31.9% | $0.68 | $0.88 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023during market hours | $180.60M | +50.4% | $0.91 | $1.15 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023during market hours | $145.70M | +18.0% | $0.49 | $0.65 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023during market hours | $140.00M | +16.3% | $0.50 | $0.62 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023during market hours | $135.00M | +11.7% | $0.66 | $0.73 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 7, 2022during market hours | $120.10M | +7.0% | $0.30 | $0.38 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022during market hours | $123.50M | – | $0.33 | $0.39 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022during market hours | $120.40M | – | $0.47 | $0.47 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 10, 2022during market hours | $120.90M | – | $0.39 | $0.42 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 8, 2021during market hours | $112.20M | – | $0.59 | $0.46 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 9, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021during market hours | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 15, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 6, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Amphastar Pharmaceuticals has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Amphastar Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Amphastar Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- News
- Results
- Results
See a number that looks wrong?